2021
Comparative Effectiveness of Echinocandins vs Triazoles or Amphotericin B Formulations as Initial Directed Therapy for Invasive Candidiasis in Children and Adolescents
Fisher B, Zaoutis T, Xiao R, Wattier R, Castagnola E, Pana Z, Fullenkamp A, Boge C, Ross R, Yildirim I, Palazzi D, Danziger-Isakov L, Vora S, Arrieta A, Yin D, Avilés-Robles M, Sharma T, Tribble A, Maron G, Berman D, Green M, Sung L, Romero J, Hauger S, Roilides E, Belani K, Nolt D, Soler-Palacin P, López-Medina E, Muller W, Halasa N, Dulek D, Bin Hussain I, Pong A, Hoffman J, Rajan S, Gonzalez B, Hanisch B, Aftandilian C, Carlesse F, Abzug M, Huppler A, Salvatore C, Ardura M, Chakrabarti A, Santolaya M, Localio A, Steinbach W. Comparative Effectiveness of Echinocandins vs Triazoles or Amphotericin B Formulations as Initial Directed Therapy for Invasive Candidiasis in Children and Adolescents. Journal Of The Pediatric Infectious Diseases Society 2021, 10: 994-1003. PMID: 34374424, DOI: 10.1093/jpids/piab024.Peer-Reviewed Original ResearchAmphotericin B formulationsInvasive candidiasisAmphotericin B groupRisk differenceExposure groupB formulationsMultinational observational cohort studyCommon invasive fungal diseaseCrude failure rateData review committeeObservational cohort studyB groupInvasive fungal diseaseMantel-Haenszel analysisCohort studyPrimary outcomePrimary exposureFailure rateComparative effectivenessCandidiasisTherapyEffectiveness dataEchinocandinsReview CommitteeChildren
2015
Risk Factors for Cardiac Toxicities Associated with Proteasome Inhibitor Chemotherapy during Treatment of Multiple Myeloma
Chen J, Lenihan D, Phillips S, Jagasia M, Goodman S, Kassim A, Lacy S, McDonagh K, Moslehi J, Sethi T, Slosky D, Ukaegbu O, Cornell R. Risk Factors for Cardiac Toxicities Associated with Proteasome Inhibitor Chemotherapy during Treatment of Multiple Myeloma. Blood 2015, 126: 5363. DOI: 10.1182/blood.v126.23.5363.5363.Peer-Reviewed Original ResearchCardiac adverse eventsIndependent risk factorCardiac eventsCumulative incidenceRisk factorsMultiple myelomaPrior historyAdverse eventsAntithrombotic therapyPI therapyMedian durationPrior linesMore patientsMale genderAtherosclerotic cardiovascular disease riskC groupCardiac Toxicity AssociatedMedian prior linesLipid-lowering medicationsB groupCardiovascular disease riskStem cell transplantationCourse of treatmentProteasome inhibitor bortezomibIncidence of PI
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply